Press Release
FERRING PHARMACEUTICALS APPOINTS OLIVIER DELANNOY AS VICE PRESIDENT, INFERTILITY BUSINESS UNIT
Contact: |
Kelly Laban |
Pictured: Olivier A. Delannoy, appointed vice president, Infertility Business Unit for Ferring Pharmaceuticals.
Suffern, NY – May 11, 2005 – Ferring Pharmaceuticals Inc. announced that Olivier A. Delannoy has been appointed vice president, Infertility Business Unit. In his new role, Delannoy will be responsible for the development and implementation of marketing and sales strategies for Ferring’s line of infertility products.
“Olivier has a proven track record within our organization,” said Wayne Anderson, president. “His extensive experience in the infertility market, coupled with his ability to translate strategy into measurable outcomes, make him uniquely suited to lead this business unit into the future.”
For the past two years, Delannoy served as vice president of sales, and prior to that was executive director of marketing, having joined Ferring in this capacity in March 1999. Before joining Ferring, Delannoy held management positions at several pharmaceutical industry firms, both in France and the U.S. In his new capacity, Delannoy is responsible for both the marketing and sales of BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP), REPRONEX® (menotropins for injection, USP) and NOVAREL® (chorionic gonadotropin for injection, USP).
About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc., part of the Ferring Group, a privately owned,
international pharmaceutical company, markets MENOPUR® (menotropins for
injection, USP), BRAVELLE® (urofollitropin for injection, purified), REPRONEX® (menotropins
for injection, USP) and NOVAREL™ (chorionic gonadotropin for injection, USP) in
the U.S. to infertility specialists and their patients. Ferring also offers the
Q∙CAP™, the first and only needle-free reconstitution device, for use with its
fertility treatments. Ferring’s line of orthopedic and urology products include
NUFLEXXA™, hyaluronic acid for pain from osteoarthritis in the knee and
DEGARELIX for prostate cancer (Phase III). Other products include ACTHREL® (corticorelin
ovine triflutate for injection) for the differential diagnosis of Cushing’s
syndrome and generic DESMOPRESSIN ACETATE in injectable and rhinal tube forms
for the treatment of diabetes insipidus and primary nocturnal enuresis. The
Ferring Group specializes in the research, development and commercialization of
compounds in general and pediatric endocrinology, urology, gastroenterology,
obstetrics/gynecology and infertility. For more information, visit
www.ferringusa.com.
# # #